Comprehensive Pediatric Solid Tumor Panel
Use
The test is designed for individuals who exhibit features indicative of hereditary pediatric cancer syndromes, those with a cancer diagnosis within the first two decades of life, individuals with multiple primary cancers, or those with two or more affected family members who developed cancer before the age of 45. The panel aims to identify genetic mutations that may contribute to these cancer predisposition syndromes, providing valuable information for diagnosis, prognosis, and potential management strategies.
Special Instructions
Not provided.
Limitations
This test has not been cleared or approved by the US Food and Drug Administration. The panel is based on NGS with CNV analysis, which may not detect all types of mutations. Variants of uncertain significance may be identified, requiring further clinical correlation. Exome-wide CNV analysis is not available for PG-Select panels, which includes this test.
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
Result Turnaround Time
7-16 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided